Drying mRNA-LNPs: Methods, Stability, and Trade-offs

Study Background and Research Question

Nucleic acid therapeutics depend on delivery systems that protect fragile genetic cargo and help it reach cells. Lipid nanoparticles (LNPs) have become a leading delivery platform for RNA, including messenger RNA (mRNA) and small interfering RNA (siRNA). Their clinical use has demonstrated the potential of nucleic acid medicines, but liquid formulations can pose storage and distribution challenges. The mRNA-LNP vaccines developed during the COVID-19 pandemic, for example, brought attention to the need for tightly controlled, often very cold storage conditions.

Zhen and colleagues address a central formulation question: can drying convert nucleic acid-LNPs (NA-LNPs) into more storage- and distribution-friendly solid products while retaining particle integrity and biological activity? Their review, Drying technologies for messenger RNA and other nucleic acid-lipid nanoparticles: advances in freeze-drying and beyond, considers both the intrinsic stability of mRNA-LNPs and the stresses introduced by drying and subsequent storage. It also asks how drying choices may need to change for nucleic acids other than mRNA.

Key Innovation from the Reference Study

The review’s main contribution is its comparative framing. Rather than treating freeze-drying as a single, transferable solution, the authors bring together evidence on conventional freeze-drying, alternative drying approaches, and multiple types of nucleic acid cargo. The review discusses mRNA alongside siRNA, self-amplifying RNA (saRNA), circular RNA (circRNA), plasmid DNA (pDNA), microRNA (miRNA), and CRISPR-related systems. This scope makes cargo structure a central consideration in evaluating the feasibility of a solid NA-LNP product.

That distinction matters because a process developed for one payload cannot be assumed to preserve another. Nucleic acids differ in size, architecture, and functional requirements, while LNP composition and particle organization also affect how a formulation responds to freezing, dehydration, and rehydration. The authors therefore position drying as a formulation-development problem involving both carrier and cargo, not simply a way to remove water. Their review also broadens the technology landscape beyond conventional freeze-drying to include continuous freeze-drying based on spin-freezing, thin-film freeze-drying, spray freeze-drying, spray drying, and alcohol dilution freeze-drying.

Methods and Experimental Design Insights

This is a literature review, not a new head-to-head experiment. Its design is comparative: it synthesizes the stability considerations for mRNA-LNPs, summarizes freeze-drying progress and challenges, and examines strategies used to protect NA-LNPs during drying and storage. It then places these approaches alongside alternative technologies and other nucleic acid payloads. The article’s value is therefore in organizing design questions and identifying where cargo-specific evidence is needed, rather than reporting one optimized recipe or a single experimentally validated process.

For experimental planning, the review supports a staged evaluation. First, characterize the liquid formulation before drying so that post-process measurements can be interpreted against a meaningful baseline. Relevant readouts include particle size and distribution, encapsulation or cargo retention, and a functional assay matched to the nucleic acid. Second, compare candidate drying approaches using the same formulation and assessment criteria where feasible. Third, evaluate the dried material after reconstitution and following the storage conditions that matter for the intended use. A dry cake or powder that appears intact is not, by itself, evidence that the LNP still delivers active cargo.

The physical stresses explain why these controls are important. During freeze-drying, ice formation can concentrate solutes in the remaining unfrozen phase, and drying removes water that contributes to the hydrated organization of lipids and nucleic acid. Reconstitution then tests whether the dried matrix can recover a usable dispersion. These are general formulation considerations for interpreting drying experiments; the review does not provide a single parameter set that can be applied across all cargoes and LNP compositions.

Protocol Parameters

• Cargo and formulation definition: Record the nucleic acid type and relevant LNP formulation attributes before selecting a drying route. This is a workflow recommendation, not a universal parameter reported by the review.
• Drying conditions: Compare candidate processes using formulation-specific development studies. Do not transfer time, temperature, or excipient settings from one NA-LNP to another without validation.
• Reconstitution assessment: Define acceptance criteria in advance for particle properties, cargo integrity, and functional potency. The review emphasizes retained stability and potency as development goals but does not establish one universal assay threshold.
• Storage evaluation: Assess the solid formulation under conditions relevant to its intended distribution and use, then repeat quality and potency measurements after reconstitution. These are study-design recommendations rather than a prescribed storage protocol.

Core Findings and Why They Matter

The review identifies freeze-drying as an important route for improving the storage stability of mRNA-LNPs, while also making clear that the process itself can threaten stability. The practical objective is not merely to obtain a dry product: it is to preserve the properties needed for delivery and biological effect through drying, storage, and reconstitution. The authors discuss strategies for maintaining stability across these stages, but the central lesson is that optimization must be specific to the formulation and its intended use.

A second finding is the need to consider cargo structure when extending drying methods beyond mRNA. The review compares drying strategies for siRNA, saRNA, circRNA, pDNA, miRNA, and CRISPR systems, underscoring that different payload architectures can have different stability requirements. Consequently, a favorable result with one nucleic acid-LNP should be treated as a starting point for, rather than proof of, performance with another. This is especially relevant when development programs move from a familiar payload to a structurally distinct one.

The alternative technologies broaden the available development choices. Continuous spin-freezing, thin-film freeze-drying, and spray freeze-drying are freeze-based approaches, while spray drying and alcohol dilution freeze-drying offer different process routes. The review presents these methods as options worth considering for stability and suitability across formulations and administration routes; it does not establish that one approach consistently outperforms conventional freeze-drying. Selection should therefore reflect the product’s required physical form, the sensitivity of its cargo and carrier, and the practical demands of processing and use.

For researchers, this comparative perspective helps avoid a common interpretive error: treating improved storage convenience as equivalent to preserved therapeutic function. A credible stability assessment needs measures that connect physical quality to cargo integrity and potency. This distinction also guides decisions about whether a drying process is useful for a particular application, rather than simply technically achievable.

Comparison with Existing Internal Articles

The internal overview Drying mRNA-LNPs: Freeze-Drying and Alternatives introduces the same broad technology landscape and stresses the need to tailor drying conditions and verify potency after reconstitution. The Zhen review provides the deeper literature context for that guidance by explicitly comparing several nucleic acid classes and distinguishing conventional freeze-drying from newer approaches. Neither source supports assuming that a method optimized for one payload will automatically work for another.

Limitations and Transferability

Because the reference is a review, it does not itself supply a standardized experimental comparison across all drying methods, payloads, and LNP compositions. Evidence assembled from different studies may involve different formulations, analytical assays, and storage conditions, limiting direct ranking of technologies. The article’s broad scope is valuable for identifying options and design considerations, but it should not be read as a universal process specification.

Transferability is particularly limited when cargo identity or intended administration route changes. A formulation’s response depends on the interaction of nucleic acid structure, lipid composition, drying process, and reconstitution conditions. Development teams should therefore reproduce relevant findings in their own formulation and use orthogonal measurements where possible. The review supports the goal of solid NA-LNPs with maintained stability and potency; it does not imply that every payload can achieve the same storage profile or that drying alone resolves all distribution constraints.

Research Support Resources

For related aqueous buffer preparation for biological assays, Potassium phosphate monobasic (KH2PO4; SKU B7291) can be considered as an enzyme assay buffer component or cell culture buffer reagent when a phosphate system is appropriate. It is a buffer-preparation reagent, not a drying stabilizer established by the review; pH control in biochemical experiments should be validated for the specific assay. The technical overview of potassium phosphate monobasic discusses its aqueous use and handling considerations.